Theriva Biologics, Inc. (TOVX)
USD 1.04
(-0.95%)
USD 1.04
(-0.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -21.02 Million USD | 47.58% |
| 2022 | -40.1 Million USD | 39.05% |
| 2021 | -65.79 Million USD | -1043.52% |
| 2020 | -5.75 Million USD | 59.83% |
| 2019 | -14.32 Million USD | 50.47% |
| 2018 | -28.91 Million USD | -68.95% |
| 2017 | -17.11 Million USD | 10.18% |
| 2016 | -19.05 Million USD | 8.47% |
| 2015 | -20.81 Million USD | -18.79% |
| 2014 | -17.52 Million USD | -19.83% |
| 2013 | -14.62 Million USD | -46.93% |
| 2012 | -9.95 Million USD | -49.06% |
| 2011 | -6.67 Million USD | -154.45% |
| 2010 | -2.62 Million USD | 2.26% |
| 2009 | -2.68 Million USD | 54.15% |
| 2008 | -5.85 Million USD | 44.71% |
| 2007 | -10.59 Million USD | 13.12% |
| 2006 | -12.19 Million USD | -953.08% |
| 2005 | -1.15 Million USD | 0.0% |
| 2002 | 11.17 Million USD | 37.25% |
| 2001 | 8.14 Million USD | 881.3% |
| 2000 | -1.04 Million USD | 44.41% |
| 1999 | -1.87 Million USD | -33.89% |
| 1998 | -1.4 Million USD | -216.67% |
| 1997 | 1.2 Million USD | 160.0% |
| 1996 | -2 Million USD | -17.65% |
| 1995 | -1.7 Million USD | -1600.0% |
| 1994 | -100 Thousand USD | 94.12% |
| 1993 | -1.7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -14.76 Million USD | 9.11% |
| 2024 Q1 | -16.24 Million USD | 22.74% |
| 2023 Q4 | -21.02 Million USD | 27.35% |
| 2023 Q2 | -31.89 Million USD | 5.11% |
| 2023 Q3 | -28.93 Million USD | 9.26% |
| 2023 FY | -21.02 Million USD | 47.58% |
| 2023 Q1 | -33.61 Million USD | 16.19% |
| 2022 FY | -40.1 Million USD | 39.05% |
| 2022 Q1 | -54.91 Million USD | 16.54% |
| 2022 Q2 | -50.56 Million USD | 7.92% |
| 2022 Q3 | -48.83 Million USD | 3.43% |
| 2022 Q4 | -40.1 Million USD | 17.88% |
| 2021 Q4 | -65.79 Million USD | 6.75% |
| 2021 Q1 | -76.48 Million USD | -1229.2% |
| 2021 Q2 | -72.66 Million USD | 4.99% |
| 2021 FY | -65.79 Million USD | -1043.52% |
| 2021 Q3 | -70.55 Million USD | 2.9% |
| 2020 Q1 | -9.42 Million USD | 34.22% |
| 2020 Q4 | -5.75 Million USD | -5.27% |
| 2020 Q3 | -5.46 Million USD | 26.7% |
| 2020 Q2 | -7.45 Million USD | 20.86% |
| 2020 FY | -5.75 Million USD | 59.83% |
| 2019 Q3 | -17.87 Million USD | 14.41% |
| 2019 FY | -14.32 Million USD | 50.47% |
| 2019 Q4 | -14.32 Million USD | 19.85% |
| 2019 Q2 | -20.87 Million USD | 12.3% |
| 2019 Q1 | -23.8 Million USD | 17.67% |
| 2018 FY | -28.91 Million USD | -68.95% |
| 2018 Q4 | -28.91 Million USD | -202.84% |
| 2018 Q3 | -9.54 Million USD | -33.95% |
| 2018 Q2 | -7.12 Million USD | 35.41% |
| 2018 Q1 | -11.03 Million USD | 35.52% |
| 2017 Q1 | -13.47 Million USD | 29.3% |
| 2017 FY | -17.11 Million USD | 10.18% |
| 2017 Q2 | -13.37 Million USD | 0.71% |
| 2017 Q4 | -17.11 Million USD | 18.69% |
| 2017 Q3 | -21.05 Million USD | -57.37% |
| 2016 Q4 | -19.05 Million USD | -318.88% |
| 2016 Q2 | -10.04 Million USD | 33.45% |
| 2016 FY | -19.05 Million USD | 8.47% |
| 2016 Q1 | -15.1 Million USD | 27.47% |
| 2016 Q3 | -4.54 Million USD | 54.73% |
| 2015 Q4 | -20.81 Million USD | 34.55% |
| 2015 Q2 | -4.75 Million USD | 60.52% |
| 2015 Q1 | -12.04 Million USD | 31.25% |
| 2015 FY | -20.81 Million USD | -18.79% |
| 2015 Q3 | -31.8 Million USD | -568.61% |
| 2014 Q4 | -17.52 Million USD | -433.32% |
| 2014 Q3 | -3.28 Million USD | 58.1% |
| 2014 Q2 | -7.84 Million USD | 29.69% |
| 2014 Q1 | -11.15 Million USD | 23.73% |
| 2014 FY | -17.52 Million USD | -19.83% |
| 2013 FY | -14.62 Million USD | -46.93% |
| 2013 Q4 | -14.62 Million USD | -184.26% |
| 2013 Q3 | -5.14 Million USD | 25.19% |
| 2013 Q2 | -6.87 Million USD | 19.28% |
| 2013 Q1 | -8.52 Million USD | 14.41% |
| 2012 Q1 | -6.8 Million USD | -1.86% |
| 2012 FY | -9.95 Million USD | -49.06% |
| 2012 Q4 | -9.95 Million USD | -117.48% |
| 2012 Q3 | -4.57 Million USD | 22.84% |
| 2012 Q2 | -5.93 Million USD | 12.79% |
| 2011 Q1 | -6.08 Million USD | -131.68% |
| 2011 Q3 | -4.6 Million USD | 45.04% |
| 2011 FY | -6.67 Million USD | -154.45% |
| 2011 Q2 | -8.38 Million USD | -37.92% |
| 2011 Q4 | -6.67 Million USD | -44.9% |
| 2010 Q3 | -3.28 Million USD | -1.14% |
| 2010 Q4 | -2.62 Million USD | 20.14% |
| 2010 FY | -2.62 Million USD | 2.26% |
| 2010 Q1 | -1.95 Million USD | 27.27% |
| 2010 Q2 | -3.24 Million USD | -66.39% |
| 2009 Q3 | -3.53 Million USD | 20.13% |
| 2009 Q2 | -4.42 Million USD | 16.38% |
| 2009 Q1 | -5.28 Million USD | 9.69% |
| 2009 FY | -2.68 Million USD | 54.15% |
| 2009 Q4 | -2.68 Million USD | 23.98% |
| 2008 Q2 | -7.45 Million USD | 14.93% |
| 2008 Q4 | -5.85 Million USD | 9.0% |
| 2008 FY | -5.85 Million USD | 44.71% |
| 2008 Q1 | -8.76 Million USD | 17.29% |
| 2008 Q3 | -6.43 Million USD | 13.65% |
| 2007 FY | -10.59 Million USD | 13.12% |
| 2007 Q3 | -6.35 Million USD | 25.8% |
| 2007 Q4 | -10.59 Million USD | -66.75% |
| 2007 Q2 | -8.56 Million USD | 17.21% |
| 2007 Q1 | -10.34 Million USD | 15.18% |
| 2006 Q4 | -12.19 Million USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | -12.19 Million USD | -953.08% |
| 2005 FY | -1.15 Million USD | 0.0% |
| 2003 Q1 | 11.33 Million USD | 1.47% |
| 2002 Q3 | 11.62 Million USD | 9.23% |
| 2002 Q2 | 10.64 Million USD | 19.02% |
| 2002 FY | 11.17 Million USD | 37.25% |
| 2002 Q1 | 8.94 Million USD | 9.86% |
| 2002 Q4 | 11.17 Million USD | -3.91% |
| 2001 Q4 | 8.14 Million USD | 182.48% |
| 2001 Q3 | 2.88 Million USD | 437.63% |
| 2001 Q1 | -381.08 Thousand USD | 63.43% |
| 2001 FY | 8.14 Million USD | 881.3% |
| 2001 Q2 | 536.03 Thousand USD | 240.66% |
| 2000 Q4 | -1.04 Million USD | -393.04% |
| 2000 FY | -1.04 Million USD | 44.41% |
| 2000 Q3 | 355.56 Thousand USD | 130.97% |
| 2000 Q1 | -1.48 Million USD | 20.62% |
| 2000 Q2 | 153.94 Thousand USD | 110.35% |
| 1999 FY | -1.87 Million USD | -33.89% |
| 1999 Q1 | -300 Thousand USD | 78.57% |
| 1999 Q2 | 200 Thousand USD | 166.67% |
| 1999 Q3 | -200 Thousand USD | -200.0% |
| 1999 Q4 | -1.87 Million USD | -837.22% |
| 1998 FY | -1.4 Million USD | -216.67% |
| 1998 Q1 | 900 Thousand USD | -25.0% |
| 1998 Q4 | -1.4 Million USD | 33.33% |
| 1998 Q3 | -2.1 Million USD | 61.11% |
| 1998 Q2 | -5.4 Million USD | -700.0% |
| 1997 FY | 1.2 Million USD | 160.0% |
| 1997 Q2 | -500 Thousand USD | 83.33% |
| 1997 Q3 | 800 Thousand USD | 260.0% |
| 1997 Q4 | 1.2 Million USD | 50.0% |
| 1997 Q1 | -3 Million USD | -50.0% |
| 1996 FY | -2 Million USD | -17.65% |
| 1996 Q4 | -2 Million USD | 42.86% |
| 1996 Q3 | -3.5 Million USD | 32.69% |
| 1996 Q2 | -5.2 Million USD | -160.0% |
| 1996 Q1 | -2 Million USD | -17.65% |
| 1995 FY | -1.7 Million USD | -1600.0% |
| 1995 Q3 | -3 Million USD | 0.0% |
| 1995 Q4 | -1.7 Million USD | 43.33% |
| 1994 Q1 | -4.4 Million USD | -158.82% |
| 1994 Q4 | -100 Thousand USD | 0.0% |
| 1994 FY | -100 Thousand USD | 94.12% |
| 1993 Q1 | -3.8 Million USD | 0.0% |
| 1993 Q4 | -1.7 Million USD | 39.29% |
| 1993 Q2 | -4.1 Million USD | -7.89% |
| 1993 Q3 | -2.8 Million USD | 31.71% |
| 1993 FY | -1.7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | -325.222% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -451.062% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 119.676% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 71.805% |
| Azitra, Inc. | -910.04 Thousand USD | -2210.113% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | -396.059% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 1893.321% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 505.302% |
| CEL-SCI Corporation | 9.42 Million USD | 323.032% |
| iBio, Inc. | -9.75 Million USD | -115.621% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 35.294% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | -193.999% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -1541.14% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 4894.911% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -5290.513% |
| NanoViricides, Inc. | -4.79 Million USD | -338.182% |
| Oragenics, Inc. | -3.17 Million USD | -563.019% |
| BiomX Inc. | -772 Thousand USD | -2623.187% |
| BiomX Inc. | -772 Thousand USD | -2623.187% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 894.22% |
| Palatin Technologies, Inc. | -8.93 Million USD | -135.234% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 251.713% |